三维适形低分割放疗联合吉非替尼治疗老年非小细胞肺癌的效果及不良反应

Efficacy and adverse reactions of three-dimensional conformal low fractionated radiotherapy combined with gefitinib in the treatment of elderly non-small cell lung cancer

目的分析三维适形低分割放疗(3D-CRT)联合吉非替尼治疗老年非小细胞肺癌(NSCLC)的效果及不良反应。方法抽取山西省肿瘤医院2017年3月至2019年1月收治的90例老年非小细胞肺癌患者作为本次研究对象,将其按随机分组方案分为对照组(45例)和观察组(45例)。对照组采用吉非替尼治疗,观察组在对照组基础上加用3D-CRT治疗。比较两组近期疗效、生活质量和不良反应。结果实施相应治疗后,观察组的卡氏功能状态评分(KPS评分)高于对照组(P<0.05)。观察组与对照组部分缓解率(PR)分别为46.7%与17.8%(P<0.05)。观察组1年、2年、3年生存率优于对照组,中位生存期亦优于对照组(P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论对老年NSCLC患者采取3D-CRT联合吉非替尼治疗,近期疗效显著,可改善患者生活质量,且安全性较好。

Objective To evaluate the efficacy and side effects of three-dimensional conformal low-segment radiotherapy (3D-CRT) combined with gefitinib in the treatment of elderly non-small cell lung cancer (NSCLC).Methods Ninety elderly patients with NSCLC treated in Shanxi Provincial Cancer Hospital from March 2017 to January 2019 were selected as the object of this study. The 90 elderly NSCLC patients were randomly divided into control group (45 cases) and observation group(45 cases) according to envelope randomized grouping scheme. The control group was treated with gefitinib, and the observation group was treated with 3D-CRT on the basis of the control group. The short-term efficacy, quality of life and adverse reactions between the two groups were compared.Results After the corresponding treatment, the KPS score of observation group of was higher than that of control group (P<0.05). The partial remission rate (PR) was 46.7% in the observation groupand 17.8% in the control group (P<0.05). The 1 year, 2 year and 3 year survival rate of the observation groupwas better than that of the control group, and the median survival rate was also better than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusions 3D-CRT combined with gefitinib can improve the quality of life of elderly NSCLC patients, and the safety is good.